NASDAQ:TTOO

T2 Biosystems (TTOO) Stock Price, News & Analysis

$2.61
-0.11 (-4.04%)
(As of 12:02 PM ET)
Today's Range
$2.60
$2.78
50-Day Range
$2.72
$6.39
52-Week Range
$2.60
$70.00
Volume
143,790 shs
Average Volume
269,419 shs
Market Capitalization
$14.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TTOO stock logo

About T2 Biosystems Stock (NASDAQ:TTOO)

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

TTOO Stock Price History

TTOO Stock News Headlines

How to camouflage a factory of 53,000 workers
"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."
T2 Biosystems, Inc. (NASDAQ:TTOO) Short Interest Update
How to camouflage a factory of 53,000 workers
"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."
T2 Biosystems Inc
Q4 2023 T2 Biosystems Inc Earnings Call
See More Headlines
Receive TTOO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/24/2024
Next Earnings (Estimated)
5/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:TTOO
Employees
113
Year Founded
N/A

Profitability

Net Income
$-50,080,000.00
Net Margins
-696.19%
Pretax Margin
-696.19%

Debt

Sales & Book Value

Annual Sales
$7.19 million
Book Value
($6.91) per share

Miscellaneous

Free Float
5,506,000
Market Cap
$14.38 million
Optionable
Optionable
Beta
0.11
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives


TTOO Stock Analysis - Frequently Asked Questions

How have TTOO shares performed in 2024?

T2 Biosystems' stock was trading at $6.28 at the beginning of 2024. Since then, TTOO shares have decreased by 58.4% and is now trading at $2.61.
View the best growth stocks for 2024 here
.

Are investors shorting T2 Biosystems?

T2 Biosystems saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 396,900 shares, an increase of 34.4% from the March 15th total of 295,400 shares. Based on an average daily volume of 255,400 shares, the short-interest ratio is currently 1.6 days. Approximately 11.6% of the shares of the company are sold short.
View T2 Biosystems' Short Interest
.

When is T2 Biosystems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024.
View our TTOO earnings forecast
.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) announced its earnings results on Thursday, November, 4th. The medical equipment provider reported ($400.00) EPS for the quarter, meeting analysts' consensus estimates of ($400.00). The medical equipment provider earned $7.43 million during the quarter. During the same period in the previous year, the firm earned ($400.00) earnings per share.

When did T2 Biosystems' stock split?

Shares of T2 Biosystems reverse split on the morning of Friday, October 13th 2023. The 1-100 reverse split was announced on Friday, October 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems issued an update on its fourth quarter 2023 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.7 million-$1.7 million, compared to the consensus revenue estimate of $2.4 million.

What is John McDonough's approval rating as T2 Biosystems' CEO?

36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT).

How do I buy shares of T2 Biosystems?

Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TTOO) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners